Published in Health Policy on May 10, 2013
Concepts of 'personalization' in personalized medicine: implications for economic evaluation. Pharmacoeconomics (2015) 1.16
From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Res Policy Syst (2015) 0.95
Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe. Int J Environ Res Public Health (2014) 0.77
Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years. Vaccine (2016) 0.75
German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health (2008) 2.20
A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics (2004) 2.15
What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics (2013) 1.41
Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison. Tob Control (2006) 1.25
Costs of inflammatory bowel disease in Germany. Pharmacoeconomics (2006) 1.19
Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics (2014) 1.17
Excess costs of dementia disorders and the role of age and gender - an analysis of German health and long-term care insurance claims data. BMC Health Serv Res (2012) 1.16
Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care (2008) 1.16
Concepts of 'personalization' in personalized medicine: implications for economic evaluation. Pharmacoeconomics (2015) 1.16
Costs of care for dementia patients in community setting: an analysis for mild and moderate disease stage. Value Health (2011) 1.15
Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis (2005) 1.14
Medical care of type 2 diabetes in German disease management programmes: a population-based evaluation. Diabetes Metab Res Rev (2011) 1.13
Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.11
The impact of ageing on hospital care and long-term care--the example of Germany. Health Policy (2004) 1.09
Preliminary analysis of short-term financial implications of a prevention bonus program: first results from the German Statutory Health Insurance. Int J Public Health (2008) 1.08
Smoking and health-related quality of life in English general population: implications for economic evaluations. BMC Public Health (2012) 1.07
Financial incentives in the German Statutory Health Insurance: new findings, new questions. Health Policy (2010) 1.06
Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. Int J Technol Assess Health Care (2010) 1.06
Relative weight-related costs of healthcare use by children--results from the two German birth cohorts, GINI-plus and LISA-plus. Econ Hum Biol (2011) 1.01
Validity, reliability and responsiveness of the EQ-5D in German stroke patients undergoing rehabilitation. Qual Life Res (2011) 1.00
Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis (2010) 0.99
Intervention study shows outpatient cardiac rehabilitation to be economically at least as attractive as inpatient rehabilitation. Clin Res Cardiol (2009) 0.97
Effectiveness and cost-effectiveness of adding a cognitive behavioral treatment to the rehabilitation of chronic low back pain. J Rheumatol (2006) 0.97
Advertising bans as a means of tobacco control policy: a systematic literature review of time-series analyses. Int J Public Health (2007) 0.97
Health-related quality of life and socioeconomic status: inequalities among adults with a chronic disease. Health Qual Life Outcomes (2014) 0.96
Economic evaluation of orthoptic screening: results of a field study in 121 German kindergartens. Invest Ophthalmol Vis Sci (2002) 0.94
Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach. BMC Health Serv Res (2011) 0.93
Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data. BMC Health Serv Res (2013) 0.92
Impact of educational level on health-related quality of life (HRQL): results from Germany based on the EuroQol 5D (EQ-5D). Eur J Public Health (2012) 0.91
Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol (2004) 0.91
Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals. BMC Neurol (2009) 0.90
Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance. J Womens Health (Larchmt) (2008) 0.90
Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines. Clin Res Cardiol (2013) 0.89
The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer. BMC Health Serv Res (2014) 0.87
Link between process and appraisal in coverage decisions: an analysis with structural equation modeling. Med Decis Making (2013) 0.86
C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients. Chest (2010) 0.86
Eliciting preferences for priority setting in genetic testing: a pilot study comparing best-worst scaling and discrete-choice experiments. Eur J Hum Genet (2013) 0.86
A structured tool to analyse coverage decisions: development and feasibility test in the field of cancer screening and prevention. Health Policy (2011) 0.86
Dementia care in the general practice setting: a cluster randomized trial on the effectiveness and cost impact of three management strategies. Value Health (2012) 0.85
The role of health technology assessment in coverage decisions on newborn screening. Int J Technol Assess Health Care (2011) 0.85
A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics (2012) 0.85
The association of smoking status with healthcare utilisation, productivity loss and resulting costs: results from the population-based KORA F4 study. BMC Health Serv Res (2013) 0.85
A comparison of different strategies to collect standard gamble utilities. Med Decis Making (2004) 0.84
Development and first assessment of a questionnaire for health care utilization and costs for cardiac patients. BMC Health Serv Res (2008) 0.84
Exposure to second-hand smoke and direct healthcare costs in children - results from two German birth cohorts, GINIplus and LISAplus. BMC Health Serv Res (2012) 0.82
Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes. Eur J Health Econ (2014) 0.81
A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv Res (2012) 0.80
Preferences, quality of life and public health. Eur J Public Health (2009) 0.80
Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data. PLoS One (2012) 0.79
Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics (2015) 0.78
Analysing coverage decision-making: opening Pandora's box? Eur J Health Econ (2014) 0.78
Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany. Pharmacoeconomics (2003) 0.78
Effects of a nurse-based case management compared to usual care among aged patients with myocardial infarction: results from the randomized controlled KORINNA study. BMC Geriatr (2013) 0.78
Cost effectiveness of external hip protectors in the hospital setting: a modeling study. Nurs Econ (2014) 0.78
A utility-theoretic approach to the aggregation of willingness to pay measured in decomposed scenarios: development and empirical test. Health Econ (2004) 0.78
Long term effects of comprehensive cardiac rehabilitation in an inpatient and outpatient setting. Swiss Med Wkly (2011) 0.77
Comparison of pre- and post-operative health-related quality of life and length of stay after primary total hip replacement in matched English and German patient cohorts. Qual Life Res (2014) 0.77
Cost-effectiveness of magnetic resonance imaging and enteroclysis in the diagnostic imaging of Crohn's disease. Int J Technol Assess Health Care (2002) 0.76
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. Pharmacoeconomics (2008) 0.76
Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data. BMC Health Serv Res (2014) 0.76
What should public health research focus on? Comments from a decision analytic perspective. Eur J Public Health (2010) 0.76
Unexpected yes- and no-answering behaviour in the discrete choice approach to elicit willingness to pay: a methodological comparison with payment cards. Int J Health Care Finance Econ (2003) 0.75
The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profiles. PLoS One (2013) 0.75
Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events. GMS Health Technol Assess (2009) 0.75
The quality of three decision-analytic diabetes models: a systematic health economic assessment. Expert Rev Pharmacoecon Outcomes Res (2011) 0.75
Promoting economic value in public health. Eur J Public Health (2008) 0.75
Cost-effectiveness of nurse-based case management versus usual care for elderly patients with myocardial infarction: results from the KORINNA study. Eur J Health Econ (2014) 0.75
[Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]. Z Evid Fortbild Qual Gesundhwes (2009) 0.75
[Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital]. Med Klin (Munich) (2002) 0.75
A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Pharmacoeconomics (2014) 0.75
Economic modelling in public health: a tool of growing relevance. Eur J Public Health (2010) 0.75
Serum antibodies against Saccharomyces cerevisiae: a new prognostic indicator in metastatic renal-cell carcinoma. Cancer Immunol Immunother (2008) 0.75